Klotho Neurosciences Reports $4.1 Million Net Loss and Seeks Additional Funding

Klotho Neurosciences, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company, which focuses on developing treatments for chronic diseases, recorded a net loss of $4.1 million for the quarter, a substantial increase from a loss of $451,639 in the same period last year. For the first half of 2025, the net loss reached $6.3 million, compared to $1.1 million for the first half of 2024. The increase in losses is attributed to higher operating expenses, which rose to $1.9 million for the quarter, up from $395,607 a year earlier, driven by increased professional fees, general administrative costs, and the initiation of research and development activities.

The company’s total assets as of June 30, 2025, amounted to $10.8 million, a significant increase from $2.5 million at the end of 2024. This growth was primarily due to a substantial rise in cash and cash equivalents, which surged to $8.4 million from $63,741 at the end of the previous year. Klotho's total liabilities decreased to $195,409 from $1.3 million, reflecting a reduction in accounts payable and accrued expenses. The company’s stockholders' equity also saw a notable increase, reaching $10.7 million, compared to $1.2 million at the end of 2024.

Strategically, Klotho has made significant moves, including the completion of a business combination with Redwoods Acquisition Corp. in June 2024, which was treated as a reverse acquisition. The company has also focused on expanding its product offerings, acquiring licenses for various drug platforms, including a biosimilar biologics platform and a proprietary gene therapy platform. As of June 30, 2025, Klotho had 61,374,435 shares of common stock outstanding, reflecting its ongoing efforts to raise capital through equity financing.

Operationally, Klotho has not yet generated revenue, as it remains in a pre-revenue state. The company is actively working on its research and development initiatives, with a focus on chronic diseases such as cancer and neurodegenerative disorders. The filing indicates that Klotho is dependent on obtaining additional funding to continue its operations and execute its business plans, raising concerns about its ability to sustain operations without further capital.

Looking ahead, Klotho has expressed a need for additional working capital to support its development plans. The company has entered into a sales agreement to offer up to $50 million in common stock and filed a registration statement with the SEC to facilitate future capital raises. The management has indicated that without additional funding, there is substantial doubt about the company's ability to continue as a going concern for the next twelve months.